Breast cancer is one of the main causes of death among women in Western countries, and constitutes an important challenge for health care systems worldwide. Breast carcinomas are considered immunogenic, as adaptive responses against tumor-associated antigens have been described in both mouse models and patient. Nevertheless, breast tumors most often escape the cytotoxic activity of immune cells by hijacking the immune system. Recent successes of anti-CTLA-4 monoclonal antibodies (mAbs) (e.g., ipilimumab) in melanoma patients 1 anti-PD-1 or anti-PD-L1 mAbs in patients bearing various solid tumors (encompassing melanoma, renal cell carcinoma and lung cancer) 2 highlight cancer immunotherapy as a promising strategy for the identification of new therapeutic targets and agents that may promote antitumor immune responses, hence prolonging patient survival.
High numbers of tumor-associated (TA)-Tregs constitute an independent factor of poor prognosis for breast carcinoma patients. 3 The inducible co-stimulatory molecule (ICOS), which belongs to the CD28 protein family, is highly expressed on Tregs infiltrating various tumors, includingmelanoma and ovarian cancers. The infiltration of breast carcinoma by TA-pDCs, which is also associated with poor patient prognosis, 4 correlates with TA-Treg infiltration, and these cell subsets have been shown to co-localize within primary breast cancer lesions. 5 While pDCs from healthy donors express high levels of the unique ligand of ICOS (ICOSL) upon in vitro activation via Toll-like receptor 7 (TLR7) or TLR9, TA-pDCs isolated from tumor cell suspensions fail to express ICOSL, in spite of an activated phenotype (CD40 + HLA-DR + CD86 + ). Interestingly, the engagement of ICOSL by ICOS + T cells in vitro, leads to its downregulation at the membrane of TLR-activated pDCs, and ICOSL expression on TA-pDCs can be restored by short-term (24 h) co-culture with breast cancer cells isolated in the presence of blocking anti-ICOS mAbs. 6 Taken together, these data demonstrate that the ICOS/ICOSL interaction occurs during the interaction of TA-Tregs with TA-pDCs in breast carcinoma.
Despite their expression of Ki67 in situ, TA-Tregs do not proliferate in vitro in response to TCR stimulation with anti-CD3/anti-CD28 agonist mAbcoated beads and exogenous interleukin-2 (IL-2), contrarily to circulating Tregs or TA-Tconvs, which rapidly proliferate. Interestingly, allogeneic co-cultures, including TLR-activated pDCs and TA-CD4 + T cells, lead to a consistent expansion of FOXP3 + TA-Tregs and stimulated the secretion of IL-10. Such a pDCdependent immunosuppressive T-cell response appears to be highly dependent on ICOS, as the addition of a anti-ICOS neutralizing mAb selectively inhibits Treg proliferation and IL-10 secretion in this setting. Taken together, our data suggest blocking ICOS blockade may constitute a promising strategy to eradicate TA-Tregs and IL-10-producing CD4 + T cells in primary breast carcinoma. The neutralization of ICOS may need to be transient in order to abrogate Treg amplification while leaving unperturbed the restoration of effector cells potentially expressing ICOS. The efficacy of ICOS blockade as a strategy for interfering with in tumor growth is currently under investigation in pre-clinical mouse models of mammary carcinogenesis.
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line with results obtained in ovarian cancer patients. 7 ICOS constitutes a critical regulator of humoral immune responses, mainly as it stimulates follicular helper T cell activation, as illustrated in ICOS-deficient mice and patients. This said, a few reports also suggest that ICOS may contribute to antitumor cellular immunity. Indeed, in melanoma patients, an increased proportion of IFNγ-producing CD4 + ICOS + T cells has been observed in patients responding to ipilumumab treatment, 9 and ICOSdeficient mice bearing B16 tumors do not respond properly to anti-CTLA-4 therapy. 8 responding to activated pDCs is also dependent on the ICOS/ICOSL interaction (Fig. 1) .
Importantly, neither IL-2, IL-17 or interferon γ (IFNγ) are detectable in dissociated breast carcinoma, in contrast to IL-10. 6 The neutralization of ICOS increases the secretion of IL-2 in TA-CD4 + T cells/pDC co-cultures but only slightly reduces the secretion of IFNγ and the proliferation of Tconvs, and does not impact T-cell responses to mDCs. This suggests that ICOS favor TA-Treg expansion and IL-10 secretion but does not participate in the induction of immune effectors against primary breast cancer lesions. Importantly, in a retrospective clinical study involving a cohort of breast carcinoma patients, ICOS expression (as assessed by immunohistochemistry) was mainly detected on TA-Tregs and ICOS + cell infiltration correlated with reduced disease free and overall survival in univariate analyses, 6 in
